VANCOUVER, B.C., April 13, 2023 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced that it will present two posters – a clinical poster (#CT149) and a translational research poster (#2259) – at the…